Insulet (PODD) EBITDA (2010 - 2026)

Insulet (PODD) has reported EBITDA for 17 consecutive years, with $129.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 7.1% year-over-year to $129.7 million; the trailing twelve-month figure through Jun 2026 stood at $515.8 million (up 26.64% YoY), and the FY2025 full-year result was $473.8 million, up 53.38% from the prior year.
• EBITDA climbed to $129.7 million in Q2 2026 per PODD's latest filing, from $122.1 million in the prior quarter.
• Across five years, EBITDA topped out at $146.3 million in Q4 2025 and bottomed at -$26.7 million in Q2 2022.
• Historically, EBITDA has averaged $71.8 million across 5 years, with a median of $72.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 201.52% in 2022, then surged 1789.66% in 2023.
• Over 5 years, EBITDA stood at $23.5 million in 2022, then surged by 353.19% to $106.5 million in 2023, then advanced by 2.63% to $109.3 million in 2024, then jumped by 33.85% to $146.3 million in 2025, then retreated by 11.35% to $129.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $129.7 million, $122.1 million, and $146.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.